Neuroendocrine Articles & Analysis
12 news found
Food and Drug Administration (FDA) has granted the company Fast Track designation for ITM-11 (n.c.a. 177Lu-edotreotide), an investigational radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM-11 is being evaluated as a Targeted Radionuclide Therapy in two phase III clinical trials, COMPETE and COMPOSE. ...
Event: Cantor Neurology & Psychiatry Conference – October 6th - 7th Panel: “Broken circuits. Modulating the neuroendocrine systems to reestablish equipoise.” Friday, October 7th at 10:10-11:10 AM PT (1:10-2:10 PM ET) 1x1 Meetings: Management will be available for one-on-one meetings October 6th & 7th The panel presentation will be available only to ...
“I look forward evaluating the use of LUM-201 for patients with NAFLD," said Laura Dichtel, MD, Assistant Professor, Harvard Medical School, Department of Endocrinology, Neuroendocrine Unit. "Prior studies have demonstrated growth hormone’s potential to treat NAFLD, given the hormone’s lipolytic actions in addition to its role as an anti-inflammatory cytokine. ...
It will be evaluated in both solid tumors, such as small cell lung cancer and neuroendocrine prostate cancer and hematological cancers such as acute myelogenous leukemia, myelodysplastic syndrome, and other myeloproliferative ...
BXCL701 is being evaluated in combination with KEYTRUDA® (pembrolizumab) in an ongoing Phase 2 trial in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype. Most recently, the Company announced positive efficacy and safety data at the 2022 ASCO Genitourinary Cancers Symposium, ...
About carcinoid syndrome Carcinoid syndrome is a rare condition that affects about a fifth of patients with well-differentiated neuroendocrine tumours (NETs) during the course of their disease and CSD occurs in about 80% of these patients. ...
Curasight A / S ("Curasight" or "The Company") announces today that it is expanding and accelerating its clinical programs with two additional cancer indications - Neuroendocrine tumors (NET) and head and neck cancer. Both indications will be pursued with regard to both diagnostics and therapy meaning that Curasight strengthens its position as a theranostic company. ...
(Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced results from its ongoing Phase 2 trial of BXCL701, the Company's investigational, oral innate immunity activator, in metastatic castration-resistant prostate cancer (mCRPC) patients with either ...
The collaboration will focus on the discovery and development of novel therapies targeting immune checkpoint proteins for the treatment of neuroendocrine tumors and other cancers. Dr. Steven K. Libutti, Director of Rutgers Cancer Institute of New Jersey, Vice Chancellor of Cancer Programs, Rutgers Biomedical and Health Sciences, and Senior Vice President of Oncology Services, ...
The study demonstrates strong prognostic value and that uPAR is expressed in the majority of neuroendocrine tumor patients. The abstract of the article is freely available here (https://pubmed.ncbi.nlm.nih.gov/35058319/). The phase II study The phase II trial (NCT03278275) aimed to evaluate the expression of uPAR in neuroendocrine tumor (NET) patients as well ...
Priest also managed a research group at Bayer Biotechnology and was an assistant professor at the University of Maryland School of Medicine, where her lab focused on neuroendocrine modulation of behavior and neural circuitry. Dr. Priest received a Ph.D. in neuroanatomy and cell biology from the University of California at Los Angeles School of Medicine, and a bachelor’s ...
Camurus (NASDAQ STO: CAMX) today announces that dosing has been initiated in the company’s randomized, active-controlled Phase 3 study, SORENTO, which aims to evaluate the efficacy and safety of octreotide subcutaneous depot (CAM2029) in the treatment of patients with neuroendocrine tumors localized in the gastrointestinal tract or pancreas (GEP-NET). “There is a ...